All News

Often uncovered by accident, appendiceal cancers trigger few symptoms until they’re advanced and can be difficult to detect and treat.

I confronted my oncologist and dentist about the research I found. After doing their own research, they told me that cancer and treatment can weaken bone structure including teeth. I wish I had been told this earlier.

The Food and Drug Administration noted the trial design was acceptable for researchers to evaluate VERU-111 in in metastatic castration and novel androgen-blocking agent resistant prostate cancer.

The FDA has approved a generic form of the intravenous chemotherapy pemetrexed for use by itself in patients with locally advanced or metastatic non-squamous non-small cell lung cancer that has not progressed following four cycles of initial platinum-based chemotherapy.

The agent, in combination with the current standard of care, is being evaluated as a frontline treatment for patients with high-risk Denovo Genomic Marker 1 (DGM1)–positive DLBCL.

“Through patients’ eyes, augmented intelligence may improve health care quality but should be implemented in a manner that preserves the integrity of the human physician-patient relationship,” the authors wrote.

At a median follow-up of 10 months, all patients who received Tafinlar plus Mekinist achieved an overall response rate of 51%.

On social media, CURE® recently asked its readers to share some tips for others for coping with roadblocks they might experience on their cancer journey. Here, we share some of their responses.

Dr. Jennifer L. Atlas notes that while these results could lead to a paradigm shift, surgery and radiation aren’t being eliminated as treatment options.

After lifesaving medicine became available to treat hepatitis C virus, a risk factor for liver cancer, racial inequities in the death rate from the malignancy began a steady upward climb.

From the bi-partisan Research to Accelerate Cures and Equity (RACE) for Children Act implementing an FDA mandate that all new cancer therapies for adults must also be studied in children, to the “Iron Man” of baseball Cal Ripken Jr. announcing he’s cancer free after a February diagnosis, here’s what’s happening in the cancer landscape this week.

Specific measures of a tumor’s texture and intensity as they appear on CT images can help determine how much treatment patients with early stage lung cancer need, a study found.

The Food and Drug Administration (FDA) has approved the expansion of Kyprolis (carfilzomib) in combination to with Darzalex (daratumumab) plus dexamethasone in once- and twice-weekly dosing regimens for the treatment of patients with relapsed or refractory multiple myeloma who have received a maximum of three prior lines of therapy.

Circulating tumor DNA and circulating tumor cells are usual markers for minimal residual disease in patients with triple negative breast cancer, but new research shows they are also valuable indicators of disease recurrence.

In addition to not delaying disease worsening, the immunotherapy Tecentriq was associated with a negative survival trend, but data on the length of life were immature at the time of analysis and further analysis is planned.

“With data showing a two-fold increase in disease-free survival with the vaccine alone and in combination with checkpoint inhibitors, we hope to one day change the narrative for people with melanoma — turning this disease into a chronic condition that can be treated and managed over time,” said Dr. Mark B. Faries.

“This study has highlighted the potential benefit of supportive resources to help women with (metastatic breast cancer) guard against potentially severe cancer-related financial losses for themselves and others within their households,” the authors wrote.

If approved by the FDA, Imfinzi could be administered every four weeks at a fixed dose in patients with stage 3 NSCLC after they received chemoradiation, as well as in patients with previously treated bladder cancer.

While 75% of patients with gynecological cancers and COVID-19 will recover, new data from New York City shows specific risks for patients with cancer infected with COVID-19.

The Food and Drug Administration granted a priority review to the new drug application for trilaciclib for patients with small cell lung cancer.

New research has found that the risk for invasive prostate cancer increases significantly when patients have a family history of PBSIN along with invasive prostate cancer.

From the recent Beirut explosion compromising pediatric oncology hospitals, to researchers looking at how intestinal bacteria can supercharge targeted immunotherapies, here’s what’s happening in the cancer landscape this week.

In patients with diffuse large B-cell lymphoma, low muscle mass (LMM) and low muscle density (LMD) could play a role when deciding what kind of treatment option to pursue, and could also impact a patient’s odds of survival, according to a recent study.

For newly diagnosed patients with ovarian cancer, a recent study shows how too much chemotherapy can lead to less favorable results.

“Unlike other CAR T-cell therapies, clinical success was not associated with significant complications from therapy,” said Dr. Jonathan Serody. “This means this treatment should be available to patients in a clinic setting and would not require patients to be hospitalized, which is critical in our current environment.”

“These results further support our efforts to reimagine medicine in this incurable malignancy and reach this underserved patient population, who are historically burdened with several years of various treatments,” said Dr. John Tsai.

A roundup of the latest news and updates for patients with mantle cell lymphoma from CURE®.

“This study comes from a very honest place. Because I want all patients out there with lung cancer to feel empowered to ask their doctor because they don't have to suffer in silence,” said Dr. Narjust Duma.